2014 Spring Meeting of Participants
SPECIAL PLENARY SESSION AND AWARDS CEREMONY
Friday, May 2, 2014
4:30 – 6:00 pm

Special Plenary Session – Dr. Penny Bradbury, Chair

<table>
<thead>
<tr>
<th>Topic</th>
<th>Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>BR.26: A Double Blind Placebo Controlled Randomized Trial of PF-804 in Patients With Incurable Stage IIIB/IV Non-small Cell Lung Cancer After Failure of Standard Therapy for Advanced or Metastatic Disease</td>
<td>Dr. Peter Ellis</td>
</tr>
<tr>
<td>Estimation of Cost Avoidance in NCIC CTG Phase III Clinical Trials</td>
<td>Dr. Patricia Tang</td>
</tr>
<tr>
<td>IND.206: A Phase II Study of Sunitinib or Temsirolimus in Patients with Advanced Rare Tumours</td>
<td>Dr. Hal Hirte</td>
</tr>
<tr>
<td>LY.12: Randomized Phase III Study of Gemcitabine, Dexamethasone, Cisplatin (GDP) Compared to Dexamethasone, Cytarabine, Cisplatin (DHAP) Chemotherapy Prior to Autologous Stem Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas – Part 2</td>
<td>Dr. Michael Crump</td>
</tr>
</tbody>
</table>

NCIC CTG Awards Ceremony – Dr. Elizabeth Eisenhauer, Chair

- **Joseph Pater Founder’s Award for Excellence in Clinical Trials Research**
  - 2014 Recipient – Dr. Vivien Bramwell

- **Ralph Meyer Phase III Young Investigator Award**
  - 2014 Recipient – Dr. Annette Hay

- **Elizabeth Eisenhauer Early Drug Development Young Investigator Award**
  - 2014 Recipient – Dr. Daniel Renouf

- **Early Drug Development Team Award**
  - 2014 Recipients:
    - IND.211 – CHUM Hôpital Notre-Dame
    - IND.210 – Ottawa Hospital Research Institute

- **Phase III Program Team Award**
  - 2014 Recipients:
    - MA.32 – Vancouver Centre - BC Cancer Agency
    - BR.26 – Princess Margaret Cancer Centre